© 2024 Corcept Therapeutics, Incorporated
Open-label Extension Study Evaluating the Safety and Efficacy of Long-term Use of Relacorilant in Patients With Endogenous Hypercortisolism (Cushing Syndrome): Interim Analysis Results
Araque et al. • 2024 • WCIRDC
Medical Treatment of Hypercortisolism with Relacorilant: Final Results of the Phase 3 GRACE Study
Araque et al. • 2024 • WCIRDC
Prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes and cardiovascular disease: Results from CATALYST
Fonseca et al. • 2024 • WCIRDC
Prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes and high blood pressure: Results from CATALYST
Handelsman et al. • 2024 • WCIRDC
Open-label Extension Study Evaluating the Safety and Efficacy of Long-term Use of Relacorilant in Patients With Endogenous Hypercortisolism (Cushing Syndrome): Results from the First Interim Analysis
Badiu et al. • 2024 • AACE MENA 2024 Congress
Relacorilant Maintained Hypertension Improvement in Long-term Follow-up of Patients With Endogenous Hypercortisolism (Cushing Syndrome)
Gilis-Januszewska et al. • 2024 • AACE MENA 2024 Congress
Hypercortisolism Impact on Hypertension and Hyperglycemia and Beyond
Ralph A. DeFronzo • 2024 • Heart in Diabetes 2024
Posted with permission of the presenter.
Posted with permission of the presenter.
Medical Treatment of Hypercortisolism with Relacorilant: Final Results of the Phase 3 GRACE Study
2024 • Heart in Diabetes 2024
Results From Grace, a Phase 3 Double-blind, Randomized-withdrawal Study of the Selective Glucocorticoid Receptor Modulator Relacorilant for the Treatment of Endogenous Hypercortisolism (Cushing Syndrome)
2024 • ENDO 2024